Phil Lieberman

Summary

Publications

  1. ncbi The risk and management of anaphylaxis in the setting of immunotherapy
    Phil Lieberman
    Allergy and Asthma Care, Germantown, Tennessee 38138, USA
    Am J Rhinol Allergy 26:469-74. 2012
  2. ncbi The diagnosis and management of anaphylaxis practice parameter: 2010 update
    Phillip Lieberman
    JointCouncil of Allergy, Asthma and Immunology, 50NBrockway St, 3 3, Palatine, IL 60067, USA
    J Allergy Clin Immunol 126:477-80.e1-42. 2010
  3. ncbi Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis
    Phil Lieberman
    Allergy and Asthma Care, Germantown, Tennessee 38138, USA
    Allergy Asthma Proc 32:151-8. 2011

Detail Information

Publications3

  1. ncbi The risk and management of anaphylaxis in the setting of immunotherapy
    Phil Lieberman
    Allergy and Asthma Care, Germantown, Tennessee 38138, USA
    Am J Rhinol Allergy 26:469-74. 2012
    ..Anaphylactic events due to immunotherapy are probably not completely preventable. There is always an inherent risk surrounding the administration of an allergen to an individual who is sensitized to the substance administered...
  2. ncbi The diagnosis and management of anaphylaxis practice parameter: 2010 update
    Phillip Lieberman
    JointCouncil of Allergy, Asthma and Immunology, 50NBrockway St, 3 3, Palatine, IL 60067, USA
    J Allergy Clin Immunol 126:477-80.e1-42. 2010
    ..These parameters are not designed for use by pharmaceutical companies in drug promotion...
  3. ncbi Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis
    Phil Lieberman
    Allergy and Asthma Care, Germantown, Tennessee 38138, USA
    Allergy Asthma Proc 32:151-8. 2011
    ..OLO has a similar efficacy and safety profile to AZE for the management of VMR in patients ≥12 years of age...